ALLOGENE THERAPEUTICS INC. - COMMON STOCK

Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ Products

14 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Preclinical Data on ALLO-316, an AlloCAR T™ Candidate Targeting CD70 for the Treatment of Renal Cell Carcinoma, at AACR’s Annual Meeting and in Cancer Research Journal

13 Apr 2022 09:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Seven Upcoming Investor Conferences

12 Apr 2022 08:30:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Preclinical Publication Highlighting Superiority of Healthy Donor-Derived Allogeneic CAR T Cells Over Patient-Derived Cells in Multiple Myeloma

23 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Receives FDA Fast Track Designation for its First Solid Tumor Candidate, ALLO-316 in the Treatment of Renal Cell Carcinoma

10 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Publishes Inaugural Environmental, Social and Governance (ESG) Report

01 Mar 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

23 Feb 2022 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results on February 23, 2022

16 Feb 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Four Upcoming Virtual Investor Conferences

26 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Exclusive Collaboration and Global License Agreement with Antion Biosciences for Multiplex miCAR™ Technology

11 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Removal of FDA Clinical Hold Across All AlloCAR T™ Clinical Trials

10 Jan 2022 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 08:30:01 By Nasdaq GlobeNewswire

Allogene Therapeutics Expands Headquarters to Support Company Growth and Pipeline Innovation

15 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting

13 Dec 2021 11:00:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology

13 Dec 2021 10:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Conference Call to Review ALPHA, ALPHA2 and UNIVERSAL Phase 1 Data Presented at the 2021 American Society of Hematology Annual Meeting

01 Dec 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Announces Participation in Five Upcoming Virtual Investor Conferences

12 Nov 2021 08:30:00 By Nasdaq GlobeNewswire

Allogene Therapeutics Reports Third Quarter 2021 Financial Results and Business Update  

04 Nov 2021 16:02:00 By Nasdaq GlobeNewswire

Allogene Therapeutics to Showcase Clinical Data from the ALPHA, ALPHA2 and UNIVERSAL AlloCAR T™ Trials at the 63rd Annual Meeting of the American Society of Hematology

04 Nov 2021 09:05:39 By Nasdaq GlobeNewswire

Allogene Therapeutics to Report Third Quarter Financial Results on November 4, 2021

28 Oct 2021 08:30:00 By Nasdaq GlobeNewswire